Author

Cem Kayhan 1

1 Eli Lilly and Company,

BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS

Marla C. Dubinsky, April Naegeli, Mingyang Shan, Sylvie Bradesi, Jochen Schmitz, Catherine Milch, Cem Kayhan, Simon Travis

COMPARATIVE EFFICACY AND SAFETY OF TOFACITINIB AND BIOLOGICS AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin, Ajibade O Ashaye, Younan Zhang, yingxin xu, Kyle Fahrbach, Lea Ann Chen, Alireza Manuchehri, Cem Kayhan, John Woolcott, Joseph C. Cappelleri

EFFICACY OF TOFACITINIB AND BIOLOGICS AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin, Ajibade O Ashaye, Younan Zhang, Kyle Fahrbach, Andreas Freitag, Cem Kayhan, Christoph Lohan, Joseph C. Cappelleri, Marco DiBonaventura

Item 1 - 3 / 3
1